Research
Hormonal
SELECT demonstrated a significant reduction in major adverse cardiovascular events in adults with overweight or obesity and established atherosclerotic cardiovascular disease, independent of diabetes status.
Semaglutide may significantly lower the risk of cardiovascular events in at-risk populations.
StrongSupportsmedium confidence
SELECT demonstrated a significant reduction in major adverse cardiovascular events in adults with overweight or obesity and established atherosclerotic cardiovascular disease (ASCVD), independent of diabetes status.
Why this rating
Based on results from a major cardiovascular outcomes trial.
Source
National Consensus on Semaglutide in Cardiology: From Clinical Evidence to Clinical Translation
HK Chopra et al. · Journal of the Association of Physicians of India · 2026
Meta-analysisCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →